Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Porter C A, Rifkin R M. Clinical benefits and economic analysis of pegylated liposomaldoxorubicin/vincristine/dexamethasone versus doxorubicin/vincristine/dexamethasone inpatients with newly diagnosed multiple myeloma. Clinical Lymphoma and Myeloma 2007; 7(Supplement 4): S150-S155 Indexing Status Subject indexing assigned by NLM MeSH Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols /adverse effects /economics /therapeutic use; Cost-Benefit Analysis; Dexamethasone /administration & Disease Progression; Doxorubicin /administration & Female; Health Resources /utilization; Humans; Length of Stay /economics; Liposomes; Male; Middle Aged; Multiple Myeloma /diagnosis /drug therapy; Outcome Assessment (Health Care); Polyethylene Glycols /administration & Survival Rate; Time Factors; Treatment Outcome; Vincristine /administration & derivatives /economics; dosage /adverse effects /analogs & dosage /adverse effects /economics; dosage /adverse effects /economics; dosage /adverse effects /economics AccessionNumber 22007001343 Date bibliographic record published 25/07/2007 |